SBIR Phase II: High multiplex visual mapping of heterogeneity in FFPE biospecimen

SBIR 第二阶段：FFPE 生物样本异质性的高度多重视觉绘图

• 批准号: 1758649
• 负责人: Dmitry Derkach
• 金额: $ 73.51万
• 依托单位: BioSyntagma, LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-02-01 至 2020-07-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1758649&HistoricalAwards=false
• 关键词: SBIR; Phase; II; multiplex; visual

This SBIR Phase II project aims to facilitate understanding of cellular diversity in tumors, a phenomenon that contributes to acquired drug resistance. Quantifying and understanding this diversity may help predict a patient?s response to certain drugs which would allow the selection of ideal drug combinations for an individual patient?s tumor, thus enabling personalized medicine. This Phase II project will provide drug developers and researchers with a tool that can quantify diversity by correlating genetic and spatial information from tumors, providing crucial information about tumor composition that is currently missing today. This project will translate the technology into an efficient, high-throughput workflow that will enable commercialization with drug developers, researchers, and reference laboratories, generating both income and multiple job opportunities. The commercialization of this innovation will significantly impact scientific, corporate, and patient communities. Researchers will have a new tool improving drug development for cancer and other diseases, including Alzheimer?s and diabetes. Payers, such as insurance companies and the government, will save costs by eliminating unnecessary spending on treatments for patients who will not respond. Most importantly, patients will have broader access to personalized medicine through new treatments and screening methods that can help determine the optimum drug combinations for them.A single tumor contains multiple populations of cells that each have unique mutations, and it is necessary to understand the location and genetic differences of these cells in order to provide effective combination therapies that will not result in overall treatment failure or relapse. This Phase II project aims to provide drug developers, researchers, and physicians with a tool to correlate genetic and spatial information about individual tumors. Using a proprietary microfluidic device adhered to a standard microscope slide and tissue biopsy, incorporated with a laser-coupled microscope, this tool is capable of providing information that it is not possible to obtain from any other method today. Building upon the feasibility established during the Phase I project, Phase II will involve performing NGS to demonstrate the instrument?s usefulness in providing data for clinical research and biomarker discovery. It will also involve building a fully integrated prototype instrument with features that increase automation and throughput to make the technology economically feasible for commercialization. These developments will showcase the instrument?s value to customers as well as enable the commercial launch of a service.

SBIR第二阶段项目旨在促进对肿瘤细胞多样性的理解，这是一种有助于获得性耐药性的现象。量化和理解这种多样性可能有助于预测患者？患者对某些药物的反应，从而为个体患者选择理想的药物组合？的肿瘤，从而实现个性化医疗。这个II期项目将为药物开发人员和研究人员提供一种工具，可以通过关联肿瘤的遗传和空间信息来量化多样性，提供目前缺少的关于肿瘤组成的关键信息。该项目将把这项技术转化为一个高效、高通量的工作流程，使药物开发人员、研究人员和参考实验室能够实现商业化，从而创造收入和多种就业机会。这项创新的商业化将对科学、企业和患者社区产生重大影响。研究人员将有一个新的工具，改善药物开发的癌症和其他疾病，包括阿尔茨海默病？s和糖尿病。保险公司和政府等付款人将通过消除对无反应患者的不必要治疗支出来节省成本。最重要的是，通过新的治疗和筛选方法，患者将有更广泛的机会获得个性化的药物，这些方法可以帮助确定最佳的药物组合。单个肿瘤包含多个细胞群，每个细胞群都有独特的突变，并且有必要了解这些细胞的位置和遗传差异，以便提供有效的联合疗法，而不会导致整体治疗失败或复发这个第二阶段项目旨在为药物开发人员，研究人员和医生提供一种工具，以关联个体肿瘤的遗传和空间信息。使用粘附在标准显微镜载玻片和组织活检上的专有微流体装置，结合激光耦合显微镜，该工具能够提供当今任何其他方法都无法获得的信息。在第一阶段项目建立的可行性基础上，第二阶段将涉及执行NGS来演示仪器？在为临床研究和生物标志物发现提供数据方面的有用性。它还将涉及建立一个完全集成的原型仪器，具有提高自动化和吞吐量的功能，使该技术在商业化方面经济可行。这些发展将展示该文书？的价值，以及使商业推出的服务。